How Boosting a Natural Egg Pathway Could Transform Reproductive Medicine – Ovo Labs
Ovo Labs shared a post on LinkedIn:
“We’re very excited to see our innovative approach to restoring human egg quality featured in The Washington Post!
As highlighted by independent experts quoted in the article, our first-in-class approach validated in human eggs in vitro is unconventional because it enhances a pathway that naturally exists in the human egg – but whose effectiveness declines as women and their eggs age. With our EmbryoProtect therapeutic, we boost the protective capacity of Shugoshin1 (Japanese for ‘protective spirit’), helping both younger and older eggs reach their full potential.
Huge congratulations once again to all the study authors from Prof. Melina Schuh lab at the Max Planck Institute for Multidisciplinary Sciences – especially Debojit Saha, first author of the manuscript preprint – and to our team at Ovo Labs (Melina Schuh, Agata Zielinska, Oleksandr Yagensky, Saba Manshaei, Hyukjoon Jeon, Mila Zemyarska-Karcheva, Daniel Veselinovic), who are now working hard to translate this discovery into a real therapy for patients
Link to the article here.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 1, 2026, 13:32Pregnancy Loss Leave and Recognition in Ireland! – PLRG
-
Apr 1, 2026, 13:19Christopher Robinson: Immune Tolerance Breakdown In Pregnancy!
-
Apr 1, 2026, 13:14How Many Cells Are Enough in Blastocyst Biopsy? – Fertility Plus
-
Apr 1, 2026, 13:09Follicular Fluid PFAS May Influence IVF Outcomes – Fertility and Sterility
-
Apr 1, 2026, 12:48Taarika Ramesh: Rethinking IVF Stimulation With Progestin-Primed Protocols
-
Apr 1, 2026, 12:41Shivam Jha: What is the Importance of Ultrasound During Pregnancy?
-
Apr 1, 2026, 12:18Abnormal Spermogram Is Not an Explanation, It Is a Starting Point – Cesar Fertility
-
Apr 1, 2026, 11:41Christopher Robinson: Racial Disparities in Postoperative Benign Hysterectomy Outcomes
-
Apr 1, 2026, 11:26Sergei Gorlovetsky: Most Fertility Clinics Are Losing Patients Between Interested and Started Treatment